RASTETTER WILLIAM H — SEC insider filings
SEC reporting owner CIK 1205903. 41 insider filings on record with FilingPulse; latest filed 2026-11-20.
Transaction summary — filings shown
Covers all 41 filings on record, filed 2021-04-02 to 2026-11-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 8 filings — 96,118 shares, $11,764,390 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 68.
- Largest priced transaction: sale of 30,000 shares @ $110.20 ($3,305,952) in NEUROCRINE BIOSCIENCES INC, filed 2025-05-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Director | 14 | — | 8 legs · 95,259 sh · $11,764,008 | 24 |
| Dare Bioscience, Inc. (DARE) | Director | 8 | — | 1 leg · 859 sh · $382 | 7 |
| Regulus Therapeutics Inc. (RGLS) | Director | 8 | — | — | 17 |
| FATE THERAPEUTICS INC (FATE) | Director | 8 | — | — | 12 |
| Iambic Therapeutics, Inc. (IAM) | Director | 3 | — | — | 8 |
Insider filings — RASTETTER WILLIAM H
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-20 | 4 | Dare Bioscience, Inc. (DARE) | Sale (S): 859 @ $0.45 | EDGAR |
| 2026-10-19 | 4 | Iambic Therapeutics, Inc. (IAM) | Conversion (C): 192,579 · Conversion (C): 8,341 · Conversion (C): 76,801 (derivative) @ $0 · Conversion (C): 64,001 (derivative) @ $0 · Conversion (C): 36,805 (derivative) @ $0 · Conversion (C): 14,972 (derivative) @ $0 · +1 more | EDGAR |
| 2026-10-16 | 4 | Iambic Therapeutics, Inc. (IAM) | Grant/award (A): 40,600 (derivative) @ $0 | EDGAR |
| 2026-10-14 | 3 | Iambic Therapeutics, Inc. (IAM) | Holdings only — no transactions reported | EDGAR |
| 2026-07-02 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 38,862 @ $0 | EDGAR |
| 2026-06-15 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 87,900 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | FATE THERAPEUTICS INC (FATE) | Option exercise (M): 25,000 @ $1.69 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 18,000 @ $47.89 · Sale (S): 18,000 @ $151.82 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Regulus Therapeutics Inc. (RGLS) | Code (U): 44,264 · Disposition to issuer (D): 57,292 · Disposition to issuer (D): 4,650 (derivative) · Disposition to issuer (D): 2,325 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · +4 more | EDGAR |
| 2025-05-30 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,869 @ $0 · Grant/award (A): 3,318 (derivative) @ $0 · Option exercise (M): 2,869 (derivative) @ $0 | EDGAR |
| 2025-05-07 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 30,000 @ $42.76 · Sale (S): 30,000 @ $110.20 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2024-08-16 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 14,250 @ $146.69 | EDGAR |
| 2024-06-11 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 2,869 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 20,000 @ $12.98 · Sale (S): 11,044 @ $131.47 · Option exercise (M): 20,000 (derivative) @ $12.98 | EDGAR |
| 2023-08-14 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 8,579 (derivative) @ $0 | EDGAR |
| 2023-05-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 7,625 @ $12.71 · Sale (S): 4,300 @ $101.43 · Option exercise (M): 7,625 (derivative) @ $12.71 | EDGAR |
| 2023-04-21 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,610 @ $12.71 · Sale (S): 903 @ $105.00 · Option exercise (M): 10,765 @ $12.71 · Sale (S): 6,034 @ $105.04 · Option exercise (M): 1,610 (derivative) @ $12.71 · Option exercise (M): 10,765 (derivative) @ $12.71 | EDGAR |
| 2022-06-24 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 8,650 @ $0 · Grant/award (A): 11,893 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 9,724 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 20,000 @ $6.66 · Sale (S): 10,728 @ $94.93 · Option exercise (M): 20,000 (derivative) @ $6.66 | EDGAR |
| 2021-06-24 | 4 | Dare Bioscience, Inc. (DARE) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-06-15 | 4 | Regulus Therapeutics Inc. (RGLS) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 2,681 @ $0 · Grant/award (A): 4,334 (derivative) @ $0 | EDGAR |
| 2021-05-20 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 8,833 (derivative) @ $0 | EDGAR |
| 2021-04-02 | 4/A | FATE THERAPEUTICS INC (FATE) | Gift (G): 28,461 @ $0 · Gift (G): 28,461 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1205903 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs